Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cardio- and Neurometabolic Adipobiology: Consequences and Implications for Therapy

J. Frohlich, GN. Chaldakov, M. Vinciguerra

. 2021 ; 22 (8) : . [pub] 20210416

Language English Country Switzerland

Document type Journal Article, Review

Grant support
Project 856871 - TRANSTEM H2020 Research Infrastructures
Project MAGNET (No. CZ.02.1s01/0.0/0.0/15_003/0000492 European Research Development Fund

Studies over the past 30 years have revealed that adipose tissue is the major endocrine and paracrine organ of the human body. Arguably, adiopobiology has taken its reasonable place in studying obesity and related cardiometabolic diseases (CMDs), including Alzheimer's disease (AD), which is viewed herein as a neurometabolic disorder. The pathogenesis and therapy of these diseases are multiplex at basic, clinical and translational levels. Our present goal is to describe new developments in cardiometabolic and neurometabolic adipobiology. Accordingly, we focus on adipose- and/or skeletal muscle-derived signaling proteins (adipsin, adiponectin, nerve growth factor, brain-derived neuroptrophic factor, neurotrophin-3, irisin, sirtuins, Klotho, neprilysin, follistatin-like protein-1, meteorin-like (metrnl), as well as growth differentiation factor 11) as examples of metabotrophic factors (MTFs) implicated in the pathogenesis and therapy of obesity and related CMDs. We argue that these pathologies are MTF-deficient diseases. In 1993 the "vascular hypothesis of AD" was published and in the present review we propose the "vasculometabolic hypothesis of AD." We discuss how MTFs could bridge CMDs and neurodegenerative diseases, such as AD. Greater insights on how to manage the MTF network would provide benefits to the quality of human life.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018822
003      
CZ-PrNML
005      
20210830100411.0
007      
ta
008      
210728s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms22084137 $2 doi
035    __
$a (PubMed)33923652
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Frohlich, Jan $u International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic
245    10
$a Cardio- and Neurometabolic Adipobiology: Consequences and Implications for Therapy / $c J. Frohlich, GN. Chaldakov, M. Vinciguerra
520    9_
$a Studies over the past 30 years have revealed that adipose tissue is the major endocrine and paracrine organ of the human body. Arguably, adiopobiology has taken its reasonable place in studying obesity and related cardiometabolic diseases (CMDs), including Alzheimer's disease (AD), which is viewed herein as a neurometabolic disorder. The pathogenesis and therapy of these diseases are multiplex at basic, clinical and translational levels. Our present goal is to describe new developments in cardiometabolic and neurometabolic adipobiology. Accordingly, we focus on adipose- and/or skeletal muscle-derived signaling proteins (adipsin, adiponectin, nerve growth factor, brain-derived neuroptrophic factor, neurotrophin-3, irisin, sirtuins, Klotho, neprilysin, follistatin-like protein-1, meteorin-like (metrnl), as well as growth differentiation factor 11) as examples of metabotrophic factors (MTFs) implicated in the pathogenesis and therapy of obesity and related CMDs. We argue that these pathologies are MTF-deficient diseases. In 1993 the "vascular hypothesis of AD" was published and in the present review we propose the "vasculometabolic hypothesis of AD." We discuss how MTFs could bridge CMDs and neurodegenerative diseases, such as AD. Greater insights on how to manage the MTF network would provide benefits to the quality of human life.
650    _2
$a adipokiny $x metabolismus $7 D054392
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    _2
$a metabolický syndrom $x farmakoterapie $x metabolismus $7 D024821
650    _2
$a cílená molekulární terapie $x metody $7 D058990
650    _2
$a neurotrofní faktory $x metabolismus $7 D009414
650    _2
$a neurodegenerativní nemoci $x farmakoterapie $x metabolismus $7 D019636
650    _2
$a neuropeptidy $x metabolismus $7 D009479
650    _2
$a signální transdukce $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Chaldakov, George N $u Department of Anatomy and Cell Biology and Research Institute of the Medical University, 9002 Varna, Bulgaria $u Department of Translational Stem Cell Biology, Research Institute of the Medical University, 9002 Varna, Bulgaria
700    1_
$a Vinciguerra, Manlio $u International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic $u Department of Translational Stem Cell Biology, Research Institute of the Medical University, 9002 Varna, Bulgaria
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 8 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33923652 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100411 $b ABA008
999    __
$a ok $b bmc $g 1689801 $s 1139268
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 8 $e 20210416 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a Project 856871 - TRANSTEM $p H2020 Research Infrastructures
GRA    __
$a Project MAGNET (No. CZ.02.1s01/0.0/0.0/15_003/0000492 $p European Research Development Fund
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...